You are here: Industry Insights > Prostate Cancer

News List

Marketing With safety data, Bayer could challenge Erleada, Xtandi in prostate cancer fiercepharma
February 24, 2019
For years, Johnson & Johnson and the Pfizer-Astellas team have been the only players in their class of prostate-cancer fighters. But Bayer is waiting in the wings, and stellar new safety data could make it a threat.
Opdivo Plus Yervoy Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer americanpharmaceuticalreview
February 18, 2019
Bristol-Myers Squibb Company announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer (mCRPC)....
Merck initiates three Phase III trials into Keytruda for prostate cancer pharmaceutical-technology
February 18, 2019
As a result of promising data from its Phase Ib/II KEYNOTE-365 trial, Merck has announced three new Phase III trials into the safety and efficacy of Keytruda (pembrolizumab) for patients with metastatic castration-resistant prostate cancer....
Final verdict on finasteride: Safe, effective prevention for prostate cancer worldpharmanews
January 24, 2019
Finasteride, a generic hormone-blocking drug, was found to reduce the risk of prostate cancer by 25 percent in the landmark Prostate Cancer Prevention Trial (PCPT).
Janssen announces European Commission approval of ERLEADA (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease firstwordpharma
January 17, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has granted marketing authorisation for ERLEADA® (apalutamide), a next generation oral androgen receptor inhibitor for the treatment of adult patie
the First and Only Oral Treatment for Men with Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer firstwordpharma
January 15, 2019
Astellas Pharma Canada, Inc., today announced that Health Canada approved an expanded indication for enzalutamide, an androgen receptor inhibitor for the treatment of patients with prostate cancer, following a Priority Review by Health Canada's Therapeuti
Astellas Announces Approval in Japan for the treatment of prostate cancer, Gonax for partial changes firstwordpharma
January 09, 2019
Gonax® is a GnRH receptor antagonist with a subcutaneously injectable formulation. Astellas acquired exclusive development and commercialization rights of Gonax® for the use of prostate cancer treatment in Japan from Ferring Pharmaceuticals in January 200
Sophiris slides on prostate cancer data but vows to press on fiercebiotech
December 25, 2018
Sophiris Bio is adamant that it will advance its lead drug topsalysin into phase 3 testing, after a second dose showed no additional benefit in a prostate cancer trial.....
Bayer plans filings for prostate cancer drug darolutamide pharmaphorum
December 20, 2018
Bayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped prevent the disease from spreading, in a niche where Pfizer and Johnson & Johnson have already gained a foothold.
Surgery May Benefit Some With Early Prostate Cancer: Study drugs
December 13, 2018
For certain men with early prostate cancer, choosing surgery over "watchful waiting" may add a few years to their lives, a new study suggests.....

Previous page 1 2 3 4 5 6 7 8 9 10 Next page